Zhitong Financial App News, Boan Biotech (06955) announced that the company's marketing license application for abacip intraocular injection solution (BA9101) has been submitted to Brazil's National Health Administration (ANVISA) to treat adult neovascularization (wet) age-related macular degeneration (NaMD) and diabetic macular edema (DME).
BA9101 is a biosimilar of EYLEA® (EYLEA®), which was approved for marketing in China in November 2025 (Chinese product name: Boyoujing®). As one of the key varieties of the company's global development strategy, BA9101's overseas layout is expanding at an accelerated pace. In June 2025, the company signed an exclusive licensing cooperation agreement with Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexon Pharmaceuticals, authorizing the latter to exclusively sell BA9101 in all countries and regions other than mainland China, the European Union, the United Kingdom, the United States and Japan. Currently, the registration and listing of this product in the relevant regions is progressing according to the established plan.
Based on broad patient needs and clear efficacy, BA9101 presents broad market prospects: the Brazilian pharmaceutical market will reach US$39 billion in 2024, and the compound growth rate (CAGR) is expected to be 9% from 2025; Aria®'s global sales in 2025 will reach US$5.321 billion.
The company believes that Brazil, as the top ten pharmaceutical markets in the world and number one in Latin America, is a strategic hub for pharmaceutical companies to deploy emerging markets. The submission of a marketing license application in Brazil is an important step in BA9101's process of serving patients around the world. The company will work with excellent partners to promote the application and listing of BA9101 in more countries, enhance drug accessibility for patients with retinal diseases with high-quality domestic biopharmaceuticals, and open up new growth poles for the company.